- PR Newswire•14 days agoRXi Pharmaceuticals Reports Second Quarter 2016 Financial Results and Highlights Recent Corporate Developments
MARLBOROUGH, Mass., Aug. 11, 2016 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics that address significant unmet medical ...
- PR Newswire•28 days ago
MARLBOROUGH, Mass., July 28, 2016 /PRNewswire/ -- RXi Pharmaceuticals Corporation (RXII), a clinical-stage RNAi company developing innovative therapeutics that address significant unmet medical needs, today announced that it will report its financial results for the second quarter ended June 30, 2016, and provide a business update on Thursday, August 11, 2016 after the close of the U.S. financial markets. The webcast link is available under the "Investors - Event Calendar" section of the Company's website, www.rxipharma.com. The event may also be accessed by dialing toll-free in the United States and Canada: +1 888-669-0684. RXi Pharmaceuticals Corporation (RXII) is a clinical-stage RNAi company developing innovative therapeutics that address significant high-unmet medical needs. Building on the pioneering work of RXi's Scientific Advisory Board Chairman and Nobel Laureate Dr. Craig Mello, our discovery and clinical development programs are based on our proprietary RNAi (sd-rxRNA®) platform and Samcyprone™, a topical immunomodulator.
- PR Newswire•last month
On Friday, July 29, 2016, at 2:40 p.m. EDT, during the Infection-Viral Poster Session, Dr. Karen Bulock, RXi's Vice President of Research will give an oral presentation entitled, "Diphenylcyclopropenone Ointment for the Treatment of Common Warts". The American Academy of Dermatology was founded in 1938.
RXi Pharmaceuticals Corporation (RXII)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
|Ask||14.37 x 2200|
|Day's Range||2.39 - 2.47|
|52wk Range||1.26 - 6.49|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-1.64|
|Avg Vol (3m)||64,750|
|Dividend & Yield||N/A (N/A)|